Cheat sheet

SPLE (Pharmacist) Cheat Sheet

Practice this exam

Basic Biomedical Sciences

  • 10% of exam
  • Physiology Biochemistry & Enzymology Microbiology & Immunology Molecular Genetics Pharmacogenomics Basics

Pharmaceutical Sciences

  • 35% of exam
  • Pharmacology & Toxicology Pharmacokinetics & ADME Medicinal Chemistry Pharmaceutical Calculations Sterile & Nonsterile Compounding Pharmacognosy

Social/Behavioral/Admin Sciences

  • 20% of exam
  • Saudi Pharmacy Law SFDA Regulation Pharmacovigilance Pharmacoeconomics Pharmacy Management Biostatistics & Ethics

Clinical Sciences

  • 35% of exam
  • Cardiovascular Therapeutics Endocrine Therapeutics Infectious Disease Therapeutics Respiratory Therapeutics Clinical PK & TDM Special Populations

Quick Facts

  • Exam SPLE (Pharmacist)
  • Owner SCFHS
  • Delivery Prometric CBT
  • Format 200 scored MCQs, two parts
  • Time 4h30m, one 30-min break
  • Passing score 536 on 200-800 scale
  • Question types Recall plus scenario-based
  • Eligibility SCFHS classification via Mumaris+

Competitive vs Noncompetitive Inhibition BA

Competitive

  • Raises apparent Km
  • Vmax unchanged

Noncompetitive

  • Km unchanged
  • Lowers Vmax
  • More substrate overcomes competitive inhibition only

Physiology & Biochem BA

  • Frank-Starling law Preload raises stroke volume
  • Km Substrate conc at half Vmax
  • Vmax Max rate, saturated enzyme
  • Competitive inhibitor Raises Km, same Vmax
  • Noncompetitive inhibitor Lowers Vmax, same Km
  • Beta-1 stimulation Raises heart rate, contractility

Gram-Positive vs Gram-Negative BA

Gram-Positive

  • Thick peptidoglycan wall
  • Stains purple

Gram-Negative

  • Outer membrane with LPS
  • Stains pink
  • LPS lipid A causes septic shock

Microbio, Immuno & Genetics BA

  • Gram-positive wall Thick peptidoglycan, retains violet
  • Gram-negative wall Outer membrane, LPS endotoxin
  • Lipid A Endotoxin causing septic shock
  • Type I reaction IgE-mediated, immediate anaphylaxis
  • Type IV reaction T-cell mediated, delayed onset
  • CYP2D6 poor metabolizer Low codeine to morphine conversion

Warfarin Blocks 1972 PH

  • Warfarin blocks clotting factors two, seven, nine, ten
  • II VII IX X

Solution vs Suspension PH

Solution

  • Fully dissolved
  • Clear, no settling

Suspension

  • Insoluble particles dispersed
  • Shake before use
  • Suspensions always need shaking first

Calculation Method Picker PH

  • Pediatric weight-based dosing → Clark's Rule ( mg/kg often more accurate )
  • Chemo or narrow-index dosing → Mosteller BSA formula ( Height and weight based )
  • Manual IV drip rate → gtt/min formula ( Drop factor times volume )
  • Dilute stock to lower strength → C1V1 equals C2V2 ( Solve for volume needed )
  • Mix two different strengths → Alligation tic-tac-toe method ( Differences give mixing ratio )
  • Adjust dose for renal impairment → Cockcroft-Gault CrCl estimate ( Weight, age, SCr, sex )

Pharmacology & Toxicology PH

  • Naloxone Mu-receptor antagonist, opioid reversal
  • NAPQI Toxic acetaminophen metabolite
  • N-acetylcysteine Acetaminophen overdose antidote
  • Warfarin target Inhibits VKORC1 enzyme
  • COX-1 inhibition Raises GI bleeding risk
  • COX-2 selective NSAID Raises cardiovascular thrombotic risk

Cockcroft-Gault Inputs PH

  • Age, weight, sex, and serum creatinine estimate clearance
  • Age Weight Sex SCr

Zero-Order vs First-Order Kinetics PH

Zero-Order

  • Constant amount eliminated
  • Rate independent of concentration

First-Order

  • Constant fraction eliminated
  • Rate proportional to concentration
  • Most drugs follow first-order elimination kinetics

Pharmacokinetics & ADME PH

  • Vd formula Dose over initial concentration
  • High Vd example Digoxin, about 500 L
  • Low Vd example Warfarin, about 8-10 L
  • Bioavailability F Fraction reaching systemic circulation
  • IV bioavailability 100% by definition
  • Steady state 94% reached after 4 half-lives

Pharmaceutical Calculations PH

  • C1V1 = C2V2 Dilution concentration-volume equation
  • Alligation Mixing two strengths ratio
  • Clark's Rule Weight over 150, times dose
  • Mosteller BSA Height times weight, over 3600
  • IV flow rate Volume times drop factor, over time
  • Zero-order kinetics Constant amount eliminated per time

Pharmacy Practice & Compounding PH

  • USP <797> Sterile compounding categories 1-3
  • Category 3 CSP Up to 180-day beyond-use date
  • Solution Fully dissolved, single phase
  • Suspension Insoluble solids, shake before use
  • Emulsion Two immiscible liquids, stabilized
  • Bioequivalence Same rate and extent absorbed

Pharmacognosy & Natural Products PH

  • St. John's Wort Induces CYP3A4 and P-gp
  • Ginkgo biloba Antiplatelet, raises bleeding risk
  • Digoxin source Foxglove (Digitalis) plant
  • Herbal disclosure Ask before surgery, anticoagulants
  • B12 malabsorption After gastrectomy or metformin use

SFDA vs SCFHS Roles SO

SFDA

  • Regulates drugs and devices
  • Runs pharmacovigilance (Tiyaqquz)

SCFHS

  • Licenses healthcare practitioners
  • Administers the SPLE exam
  • SFDA regulates products, SCFHS regulates people

Which Saudi Authority SO

  • Report serious adverse reaction → SFDA NPC via Tiyaqquz
  • Register or schedule a drug → Saudi Food and Drug Authority
  • License or classify a pharmacist → SCFHS through Mumaris+
  • Free chronic disease medication → Wasfaty via NUPCO pharmacies
  • Approve pharmacy formulary drug → P&T committee decision
  • Require licensed pharmacy manager → SFDA responsible-manager rule

Saudi Pharmacy Law SO

  • SFDA Regulates drugs, devices, cosmetics
  • SCFHS Licenses practitioners, runs SPLE
  • Mumaris+ SCFHS eligibility application platform
  • Controlled schedules Saudi law, Schedules I-V
  • Responsible manager Full-time licensed pharmacist required
  • Wasfaty Free chronic medication e-prescribing

Pharmacovigilance & Pharmacoeconomics SO

  • Pharmacovigilance Detects, assesses, prevents drug harm
  • NPC SFDA's national ADR monitoring division
  • Tiyaqquz SFDA's electronic ADR reporting system
  • Cost-effectiveness analysis Cost per outcome, e.g. QALY
  • QALY Quality-adjusted life year measure
  • Formulary P&T committee's approved drug list

Management, Ethics & Biostats SO

  • Informed consent Patient understands, agrees voluntarily
  • Confidentiality Protect patient health information
  • Cohort study Follows exposed group forward
  • Case-control study Starts from outcome, looks back
  • Relative risk Risk ratio between two groups
  • CPOE Computerized order entry, reduces errors

RIPE for TB CL

  • Rifampin, Isoniazid, Pyrazinamide, Ethambutol treat active tuberculosis
  • Rifampin Isoniazid Pyrazinamide Ethambutol

Trough-Only vs AUC-Guided Vancomycin CL

Trough-Only (older)

  • Target 15-20 mg/L
  • Higher nephrotoxicity risk

AUC24-Guided (current)

  • Target AUC 400-600
  • Preferred for serious MRSA
  • Use AUC24-guided dosing today

Empiric Therapy Picker CL

  • Active drug-susceptible tuberculosis → RIPE regimen, 6 months ( 2mo intensive, 4mo continuation )
  • Serious MRSA infection → Vancomycin, AUC24-guided dosing ( Target AUC24 400-600 )
  • H. pylori peptic ulcer → Triple or quadruple therapy
  • CAP with penicillin allergy → Macrolide or fluoroquinolone
  • Azole plus CYP3A4 substrate → Adjust dose or avoid ( Statin, warfarin risk rises )
  • Cultures and susceptibility return → De-escalate to narrow agent

Cardiovascular & Endocrine Therapy CL

  • First-line hypertension ACEI/ARB, CCB, or thiazide
  • BP target Below 130/80 mmHg, most adults
  • HFrEF four pillars ACEI/ARB/ARNI, beta-blocker, MRA, SGLT2i
  • Target INR 2.0 to 3.0, most indications
  • Metformin limit Avoid below eGFR 30
  • Levothyroxine Empty stomach, recheck TSH later

Four Pillars of HFrEF CL

  • ACEI/ARB/ARNI, beta-blocker, MRA, and an SGLT2 inhibitor
  • ACEI/ARB/ARNI Beta-blocker MRA SGLT2 inhibitor

Beta-1 Selective vs Nonselective CL

Beta-1 Selective

  • Metoprolol, atenolol, bisoprolol
  • Safer in asthma

Nonselective

  • Propranolol, nadolol, timolol
  • Avoid in asthma/COPD
  • Choose selective agents for reactive airways

Infectious Disease & Respiratory CL

  • RIPE regimen Rifampin, isoniazid, pyrazinamide, ethambutol
  • TB duration 2-month intensive, 4-month continuation
  • Empiric antibiotics Guided by site, local resistance
  • De-escalation Narrow therapy after culture results
  • Azole interaction Inhibits CYP3A4, raises statin levels
  • GINA asthma ICS-formoterol preferred reliever, all steps

Clinical PK & TDM CL

  • Vancomycin target AUC24 400-600 mg*h/L
  • Old vancomycin trough 15-20 mg/L, serious infection
  • Digoxin range 0.5-2.0 ng/mL, narrow index
  • Digoxin toxicity sign Yellow-green visual halos
  • Cockcroft-Gault Estimates creatinine clearance, bedside
  • Hypokalemia Increases digoxin toxicity risk

Special Populations CL

  • Pregnancy contraindication ACEI/ARB, warfarin, isotretinoin, valproate
  • Breastfeeding analgesic Short-term paracetamol usually preferred
  • Pediatric amoxicillin Weight-based mg/kg/day dosing
  • Geriatric polypharmacy Anticholinergics raise fall risk
  • CKD stage 4 Avoid standard adult NSAID dose
  • CYP2C19 poor metabolizer Reduced clopidogrel activation

Common Traps

Digoxin Level Timing

  • Draw level pre-dose only ≠ Not right after dosing

ACE Inhibitors in Pregnancy

  • Contraindicated all trimesters ≠ Fetotoxic, especially later terms

SFDA vs SCFHS Confusion

  • SFDA regulates products ≠ SCFHS licenses practitioners

Outdated Vancomycin Trough Target

  • 15-20 mg/L is old ≠ AUC24 400-600 now preferred

Km vs Vmax Inhibition

  • Competitive raises Km only ≠ Noncompetitive lowers Vmax only

Clark's Rule Limitations

  • Rough weight-based estimate only ≠ BSA more accurate, narrow-index

COX-2 Selective NSAID Risk

  • Spares GI, less bleeding ≠ Raises cardiovascular thrombotic risk

Last Minute

  • 1. SPLE has 200 scored MCQs.
  • 2. Exam splits into two 100-question parts.
  • 3. Testing time totals 4h30m.
  • 4. Passing score is 536 of 800.
  • 5. Pharma & Clinical Sciences: 35% each.
  • 6. Vancomycin targets AUC24 400-600 mg*h/L.
  • 7. Target INR is 2.0 to 3.0.
  • 8. TB regimen: RIPE for two months.
  • 9. Cockcroft-Gault estimates creatinine clearance, bedside.
  • 10. SFDA regulates drugs; SCFHS licenses pharmacists.
  • 11. Wasfaty gives free chronic-disease medications.
  • 12. USP <797> allows 180-day beyond-use dates.
  • 13. ACE inhibitors are contraindicated in pregnancy.

Saudi Pharmacist Licensure Examination (SPLE - Pharmacist)

  • Practice Questions 100 questions Study Guide 42 topics Cheat Sheet 83 facts Flashcards 50 cards Podcast